Panuveitis Treatment Global Market Report 2025

Panuveitis represents a severe inflammation affecting all layers of the eye's uvea, encompassing the iris, ciliary body, and choroid, with potential repercussions on the retina, vitreous humor, optic nerve, or eye lens. Timely and effective panuveitis treatment is crucial to mitigate inflammation, alleviate symptoms, and prevent vision loss or complications associated with the condition.

The primary drug classes employed in panuveitis treatment include anti-inflammatory medications, antimicrobial drugs, immunotherapy, and targeted therapies. Anti-inflammatory agents are substances or treatments specifically designed to reduce inflammation within the body. These therapeutic interventions can be administered through various routes, including oral and topical applications. Panuveitis treatments are utilized by diverse end-users such as hospitals, home care services, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The panuveitis treatment market research report is one of a series of new reports from The Business Research Company that provides panuveitis treatment market statistics, including panuveitis treatment industry global market size, regional shares, competitors with a panuveitis treatment market share, detailed panuveitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the panuveitis treatment industry. This panuveitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The panuveitis treatment market size has grown strongly in recent years. It will grow from $3.98 billion in 2024 to $4.35 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increased prevalence of uveitis, increased awareness and early diagnosis, improved drug delivery systems, patient advocacy initiatives, government support and regulatory approvals.

The panuveitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to personalized medicine approaches, emerging therapeutic modalities, focus on patient-centric care, global health preparedness, precision medicine initiatives, healthcare policy changes. Major trends in the forecast period include combination therapies for synergistic effects, telemedicine and remote monitoring, advancements in imaging technologies, integration of artificial intelligence, global collaborations in research.

The forecast of 9.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of immunosuppressive biologics and corticosteroid implants sourced from Switzerland and Ireland, thereby delaying vision-saving treatments and elevating ophthalmology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of eye-related diseases is expected to propel the growth of the panuveitis treatment market going forward. Eye-related diseases, also known as ocular diseases or eye conditions, are medical conditions that affect the health and function of the eyes. Panuveitis treatment reduces inflammation, prevents complications, and improves the quality of life for patients suffering from eye diseases. For instance, in December 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 20.5 million Americans over 40 had at least one cataract. Additionally, it is anticipated that approximately 30 million people will have cataract eye disease by 2028. Therefore, the increasing prevalence of eye-related diseases drives the panuveitis treatment market.

The increasing prevalence of autoimmune disorders is anticipated to drive the growth of the panuveitis treatment market in the future. The rise in autoimmune disorders can be attributed to a mix of genetic factors, environmental influences such as pollution and changes in diet, as well as greater exposure to specific infections and stressors that may lead to immune system dysregulation. These disorders are prompting advancements in panuveitis treatment by stimulating research into immune system modulation, as many panuveitis cases are associated with autoimmune activity. For example, in May 2023, the University of Oxford, a UK-based research institution, reported that autoimmune disorders impact 10% of the global population, affecting 13% of women and 7% of men. Consequently, the rising prevalence of autoimmune disorders is driving the expansion of the panuveitis treatment market.

Advancements in surgical interventions are anticipated to fuel the growth of the panuveitis treatment market in the coming years. Surgical procedures offer crucial treatment avenues for severe cases of panuveitis, addressing complications and aiding in restoring vision. These interventions encompass techniques such as vitrectomy, surgical removal of the vitreous gel in the eye, and implantation of devices or artificial intraocular lenses to manage panuveitis-related vision impairments. For example, in a clinical report published in June 2023 by the American Academy of Ophthalmology, innovative surgical approaches have shown promising outcomes in treating panuveitis complications, signifying a growing reliance on surgical interventions for managing the condition. Hence, advancements in surgical treatments are propelling the growth of the panuveitis treatment market.

Prominent enterprises engaged in the panuveitis treatment market are directing their efforts towards the development of innovative therapeutic solutions such as Xipere, aimed at providing enhanced and dependable services to their clientele. Xipere (triamcinolone acetonide) represents a corticosteroid administered via suprachoroidal injection to address macular edema induced by ocular inflammation. For instance, in February 2022, Clearside Biomedical Inc., a distinguished biopharmaceutical entity specializing in advanced drug delivery solutions for ocular diseases, introduced Xipere for treating macular edema linked to uveitis and panuveitis in the United States. Being the pioneering approved therapy containing triamcinolone acetonide, Xipere offers a preservative-free, sterile formulation designed specifically for suprachoroidal administration, utilizing Clearside's proprietary microinjector intended for the suprachoroidal space (SCS).

In July 2023, Harrow Health Inc., a US-based company, acquired Santen for an undisclosed amount. This acquisition allows Harrow to enhance its portfolio by integrating Santen's expertise in developing innovative treatments for uveitis and panuveitis. Santen Pharmaceutical Co. Ltd, based in Japan, specializes in providing treatments for panuveitis.

Major companies operating in the panuveitis treatment market report are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., Allergan Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Horizon Therapeutics PLC, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Jubilant Life Sciences Ltd., HanAll Biopharma Inc., Xbrane Biopharma AB, Alimera Science Inc., Ocular Therapeutix Inc., EyeGate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Graybug Vision Inc., Xoma Corporation, Tarsier Pharma Ltd., Vintage Labs Pvt. Ltd., Icon Bioscience Inc., Aciont Inc., Clearside Biomedical Inc., Aldeyra Therapeutics Inc.

North America was the largest region in the panuveitis treatment market in 2024. The regions covered in the panuveitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the panuveitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Panuveitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on panuveitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for panuveitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The panuveitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Anti-Inflammatory; Antimicrobial Drugs; Immunotherapy And Targeted Therapies
• 2) By Route Of Administration: Oral; Topical
• 3) By End Users: Hospitals; Home Care; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Anti-Inflammatory: Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 2) By Antimicrobial Drugs: Antibiotics; Antifungal Agents; Antiviral Medications
• 3) By Immunotherapy And Targeted Therapies: Biologic Agents; Janus Kinase (JAK) Inhibitors; Cytokine Modulators
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Pvt. Ltd.; Bausch Health Companies Inc.; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; Hoffmann-La Roche Ltd.; Allergan Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Daiichi Sankyo Company Ltd.; Horizon Therapeutics plc; Hikma Pharmaceuticals PLC; Santen Pharmaceutical Co. Ltd.; Jubilant Life Sciences Ltd.; HanAll Biopharma Inc.; Xbrane Biopharma AB; Alimera Science Inc.; Ocular Therapeutix Inc.; EyeGate Pharmaceuticals Inc.; Eyepoint Pharmaceuticals Inc.; Graybug Vision Inc.; Xoma Corporation; Tarsier Pharma Ltd.; Vintage Labs Pvt. Ltd.; Icon Bioscience Inc.; Aciont Inc.; Clearside Biomedical Inc.; Aldeyra Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.